{"id":"azd9550","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PI3K delta, AZD9550 disrupts the signaling pathways involved in B-cell activation and proliferation, leading to its therapeutic effects. This mechanism is particularly relevant in the treatment of certain types of blood cancers.","oneSentence":"AZD9550 is a small molecule that acts as a selective and potent inhibitor of the PI3K delta (p110δ) subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:24.866Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"},{"name":"Relapsed or refractory follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT07013643","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":"Healthy Participants","enrollment":75},{"nctId":"NCT06862791","phase":"PHASE2","title":"A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-18","conditions":"Obesity or Overweight","enrollment":377},{"nctId":"NCT07017179","phase":"PHASE2","title":"This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-20","conditions":"Obesity/Overweight","enrollment":871},{"nctId":"NCT06151964","phase":"PHASE1, PHASE2","title":"A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-29","conditions":"Overweight and Obesity","enrollment":118},{"nctId":"NCT05848440","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-05-02","conditions":"Non-alcoholic Steatohepatitis","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD9550","genericName":"AZD9550","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD9550 is a small molecule that acts as a selective and potent inhibitor of the PI3K delta (p110δ) subunit. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Relapsed or refractory follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}